-+ 0.00%
-+ 0.00%
-+ 0.00%

Xilio Therapeutics Q3 2024 GAAP EPS $(0.22), Inline, Sales $2.264M Miss $3.300M Estimate

Benzinga·11/07/2024 14:14:39
Listen to the news
Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.22) per share which met the analyst consensus estimate. The company reported quarterly sales of $2.264 million which missed the analyst consensus estimate of $3.300 million by 31.39 percent.